JPRN-jRCT2080222721已完成1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Provision of signed and dated, written informed consent
- •- Subjects must have a. In the escalation phase, locally advanced or metastatic NSCLC subjects who have either failed to respond or relapsed following any line of standard treatment, were unable to tolerate, or were not eligible for standard treatment
- •- a.For Escalation Phase: At least one lesion (measurable and/or non-measurable) b. For Expansion Phase: At least one measurable lesion.
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
排除标准
- •- Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.
- •- Any investigational agent, chemotherapy, immunotherapy, biologic, hormonal within 28 days of the first dose of study treatment
- •- Inadequate bone marrow reserve or organ function
研究者
相似试验
未知
1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab in combination with MEDI4736 in Japanese Patients with Advanced Solid Malignancies, and when given as a monotherapy of tremelimumab in Second- or Third-line Treatment of Japanese Subjects with Unresectable Pleural or Peritoneal Malignant MesotheliomaJPRN-jRCT2080222502AstraZeneca
已完成
1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 uUnder Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.Advanced Solid Malignancy, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial CancerJPRN-jRCT2080222792AstraZeneca KK25
未知
1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant LymphomaAdvanced Solid Malignancies, Malignant LymphomaJPRN-jRCT2080221904AstraZeneca
已完成
1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid MalignanciesJPRN-jRCT2080222811AstraZeneca
已完成
1 期
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid Malignancy, Advanced Solid TumorJPRN-jRCT2080221764AstraZeneca KK41